Yuichi Tambo

Kanazawa, Japan

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 51 publications

Prognosis following the initiation of various immune checkpoint inhibitor therapies in TTF-1-negative non-small cell lung cancer.

Prognosis following the initiation of various immune checkpoint inhibitor therapies in TTF-1-negative non-small cell lung cancer.

Journal: Cancer treatment and research communications
Published: June 25, 2026

Rechallenge with zongertinib after trastuzumab deruxtecan in HER2-mutant lung cancer: A case report.

Rechallenge with zongertinib after trastuzumab deruxtecan in HER2-mutant lung cancer: A case report.

Journal: Lung cancer (Amsterdam, Netherlands)
Published: May 31, 2026

Efficacy of ipilimumab plus nivolumab with or without chemotherapy according to baseline tumor size: a multicenter retrospective study.

Efficacy of ipilimumab plus nivolumab with or without chemotherapy according to baseline tumor size: a multicenter retrospective study.

Journal: Translational lung cancer research
Published: February 20, 2026

Survival outcomes in TTF-1 negative non-squamous non-small cell lung cancer (H-LINK 001).

Survival outcomes in TTF-1 negative non-squamous non-small cell lung cancer (H-LINK 001).

Journal: Discover oncology
Published: February 14, 2026

Nivolumab plus ipilimumab-based treatment in Japanese patients with metastatic non-small cell lung cancer and tumor PD-L1 < 1%: a pooled analysis.

Nivolumab plus ipilimumab-based treatment in Japanese patients with metastatic non-small cell lung cancer and tumor PD-L1 < 1%: a pooled analysis.

Journal: International journal of clinical oncology
Published: February 04, 2026

Efficacy and safety of necitumumab and pembrolizumab combination therapy in advanced non-small-cell lung cancer with ≥50% PD-L1 expression: A nonrandomized phase II trial.

Efficacy and safety of necitumumab and pembrolizumab combination therapy in advanced non-small-cell lung cancer with ≥50% PD-L1 expression: A nonrandomized phase II trial.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: October 31, 2025

Amphiregulin-mediated EGFR activation drives both intrinsic and acquired resistance to KRAS G12C inhibitors in KRAS G12C-mutant non-small cell lung cancer.

Amphiregulin-mediated EGFR activation drives both intrinsic and acquired resistance to KRAS G12C inhibitors in KRAS G12C-mutant non-small cell lung cancer.

Journal: Oncogene
Published: October 29, 2025

Therapeutic Strategies to Overcome Payload Resistance of Trastuzumab Deruxtecan in HER2-Positive Cancers.

Therapeutic Strategies to Overcome Payload Resistance of Trastuzumab Deruxtecan in HER2-Positive Cancers.

Journal: Cancer science
Published: September 12, 2025

Perioperative Nivolumab in Resectable Non-Small Cell Lung Cancer: A Subanalysis of Japanese Patients From CheckMate 77T.

Perioperative Nivolumab in Resectable Non-Small Cell Lung Cancer: A Subanalysis of Japanese Patients From CheckMate 77T.

Journal: Cancer science
Published: September 05, 2025

MET Enhances Amivantamab Binding to EGFR and Antibody-Dependent Cellular Toxicity.

MET Enhances Amivantamab Binding to EGFR and Antibody-Dependent Cellular Toxicity.

Journal: Cancer science
Published: July 31, 2025

Prognostic value of preoperative ctDNA and pathological venous invasion for recurrence in EGFR-mutated non-small cell lung cancer.

Prognostic value of preoperative ctDNA and pathological venous invasion for recurrence in EGFR-mutated non-small cell lung cancer.

Journal: Lung cancer (Amsterdam, Netherlands)
Published: May 10, 2025

Mechanisms of resistance to antibody-drug conjugates in cancers.

Mechanisms of resistance to antibody-drug conjugates in cancers.

Journal: Respiratory investigation
Published: March 31, 2025
Showing 1-12 of 51

Last Updated: 09/26/2026